Hensify (crystalline hafnium oxide) / Nanobiotix, J&J 
Welcome,         Profile    Billing    Logout  
 1 Disease   11 Trials   11 Trials   368 News 


«12345»
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Enrollment change, Trial termination:  NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma (clinicaltrials.gov) -  May 10, 2021   
    P1/2,  N=5, Terminated, 
    N=96 --> 5 | Active, not recruiting --> Terminated; Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enrollment change, Trial completion date, Trial primary completion date, Metastases:  NBTXR3-102: NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx (clinicaltrials.gov) -  May 10, 2021   
    P1,  N=63, Recruiting, 
    N=96 --> 5 | Active, not recruiting --> Terminated; Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape N=48 --> 63 | Trial completion date: Aug 2017 --> Sep 2022 | Trial primary completion date: Aug 2017 --> Sep 2022
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Trial completion date, Trial initiation date, Trial primary completion date:  NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) -  Apr 22, 2021   
    P1,  N=24, Recruiting, 
    The results presented here associated with the efficacy data reported previously reinforce the favorable benefit-risk ratio of the use of NBTXR3 in patients with LA STS. Trial completion date: Dec 2027 --> Mar 2024 | Initiation date: Feb 2021 --> Sep 2020 | Trial primary completion date: Jun 2023 --> Mar 2024
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Enrollment closed, Trial primary completion date:  NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma (clinicaltrials.gov) -  Apr 8, 2021   
    P1/2,  N=96, Active, not recruiting, 
    Trial completion date: Dec 2027 --> Mar 2024 | Initiation date: Feb 2021 --> Sep 2020 | Trial primary completion date: Jun 2023 --> Mar 2024 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2020 --> Nov 2021
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) -  Mar 26, 2021   
    P1,  N=34, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2027 | Initiation date: Sep 2020 --> Feb 2021 | Trial primary completion date: Mar 2024 --> Jun 2023
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer (clinicaltrials.gov) -  Mar 10, 2021   
    P1/2,  N=42, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2027 | Initiation date: Sep 2020 --> Feb 2021 | Trial primary completion date: Mar 2024 --> Jun 2023 Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Dec 2021
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enrollment open:  NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer (clinicaltrials.gov) -  Jan 14, 2021   
    P1,  N=24, Recruiting, 
    Trial completion date: Jun 2021 --> Jun 2023 | Trial primary completion date: Jun 2021 --> Dec 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Silicon-Carbide (SiC) Nanocrystal Technology and Characterization and Its Applications in Memory Structures. (Pubmed Central) -  Dec 3, 2020   
    The fabricated structures were characterized through the stress-and-sense measurements in terms of device capacitance, flat-band voltage shift, switching characteristics, and retention time. The examined electrical performance of the sample structures has demonstrated the feasibility of the application of both types of structures based on SiC nanoparticles in memory devices.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Nanoscale Tailoring of Ferroelectricity in a Thin Dielectric Film. (Pubmed Central) -  Dec 3, 2020   
    Piezoresponse force microscopy over the capacitor device revealed an asymmetrical switching of ferroelectric domains within written HfO:Ga patterns after capacitor switching, which was attributed to the mechanical stress across the doped film. The lateral spatial resolution of ferroelectricity tailoring is found to be ∼200 nm, which enables diverse applications in switchable photonics and microelectronic memories.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Clinical, Review, Journal:  Review of clinical applications of radiation-enhancing nanoparticles. (Pubmed Central) -  Nov 21, 2020   
    There are six ongoing phase 1/2 clinical trials to evaluate the combination of gadolinium-based NP and RT for the treatment of brain metastases and cervical cancer. So far, intratumoral hafnium oxide nanoparticles were safe and improved efficacy in locally advanced sarcoma.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Effects of top electrode material in hafnium-oxide-based memristive systems on highly-doped Si. (Pubmed Central) -  Nov 14, 2020   
    Repeatable, low-power, and forming-free bipolar resistive switching is obtained with both device structures, with the Au/HfO/Si devices displaying a poorer device-to-device reproducibility. Furthermore, the Au/HfO/Si devices have exhibited N-type negative differential resistance (NDR), suggesting Joule-heating activated migration of oxygen vacancies to be responsible for the SET process in the unstable unipolar mode.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  All-dielectric Multifunctional Transmittance-Tunable Metasurfaces Based on Guided-Mode Resonance and ENZ Effect. (Pubmed Central) -  Oct 26, 2020   
    The inserted periodic ITO and hafnium oxide (HfO2) layers sandwiched in silicon act as two metal-oxide-semiconductor (MOS) capacitors in a single period to disturb the resonance wavelength in the near-infrared spectral range under voltage applied...Meanwhile, the two-dimension (2D) structure works as a polarization insensitive device when setting the same structural parameters in both orthogonal directions. The proposed architectures, with various merits including ultra-compact size, high-speed and complementary metal-oxide-semiconductor (CMOS) compatibility, provides a multifunctional and multi-degree-of-freedom design, as well as enormous potential applications in more complicated flat optics.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Tunable Microwave Filters Using HfO-Based Ferroelectrics. (Pubmed Central) -  Oct 23, 2020   
    In this paper, we present microwave filters that are based on 6-nm-thick ferroelectric thin films of hafnium oxide doped with zirconium (HfZrO), which are tunable continuously in targeted bands of interest within the frequency range 0.1-16 GHz, when the applied direct current (DC) voltage is swept between 0 V and 4 V. Here, we exploit the orthorhombic polar phase in HfO through a careful doping using zirconium in an Atomic Layer Deposition (ALD) process, in order to guarantee phase stabilization at room temperature...The uniform topography, without holes, and the low surface roughness demonstrate that the composition and the structure of the film are relatively constant in volume. Three filter configurations (low-pass, high-pass, and band-pass) have been designed, modelled, fabricated, and fully characterized in microwaves, showing a frequency shift of the minimum of the reflection coefficient between 90 MHz and 4.4 GHz, with a minimum insertion loss of approximately 6.9 dB in high-pass configuration.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    [VIRTUAL] Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles () -  Oct 14, 2020 - Abstract #SITC2020SITC_1608;    
    P2/3
    This analysis revealed that NBTXR3+RT was able to broaden clonal diversity in both treated and untreated tumors, compared to RT alone. Conclusions This indicates that NBTXR3+RT has the ability to transform the tumor into a in situ vaccine more efficiently than RT alone and could have important implications for the use of NBTXR3+RT in combination with immunotherapy.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    [VIRTUAL] Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers () -  Oct 14, 2020 - Abstract #SITC2020SITC_1441;    
    P1
    Conclusions To date, NBTXR3 administration activated by SBRT in combination with anti-PD-1 treatment has been safe and well tolerated in patients with advanced cancers. Promising early signs of efficacy in anti-PD-1 naïve, as well as in patients having progressed on previous anti-PD-1 therapy will be presented.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    [VIRTUAL] Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles () -  Oct 14, 2020 - Abstract #SITC2020SITC_873;    
    P2/3
    This analysis revealed that NBTXR3+RT was able to broaden clonal diversity in both treated and untreated tumors, compared to RT alone. Conclusions This indicates that NBTXR3+RT has the ability to transform the tumor into a in situ vaccine more efficiently than RT alone and could have important implications for the use of NBTXR3+RT in combination with immunotherapy.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    [VIRTUAL] Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers () -  Oct 14, 2020 - Abstract #SITC2020SITC_706;    
    P1
    Conclusions To date, NBTXR3 administration activated by SBRT in combination with anti-PD-1 treatment has been safe and well tolerated in patients with advanced cancers. Promising early signs of efficacy in anti-PD-1 naïve, as well as in patients having progressed on previous anti-PD-1 therapy will be presented.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enrollment closed, Trial completion date, Trial primary completion date:  NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers (clinicaltrials.gov) -  Oct 6, 2020   
    P1/2,  N=200, Active, not recruiting, 
    Trial completion date: Apr 2020 --> Oct 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Sep 2023 | Trial primary completion date: Jun 2017 --> Jun 2023
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Review, Journal:  Mixed oxide nanotubes in nanomedicine: A dead-end or a bridge to the future? (Pubmed Central) -  Oct 2, 2020   
    This is followed by a review of the recent advancement of MONs in biomedical applications, including mineralization abilities, biocompatibility, antibacterial activity, cell culture, and animal testing, as well as clinical possibilities. To conclude, we propose that the combination of nanotubular surface modification with incorporating sensor allows clinicians to precisely record patient data as a critical contributor to evidence-based medicine.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Frequency mixing with HfO2 based ferroelectric transistors. (Pubmed Central) -  Sep 20, 2020   
    Recently, ferroelectric field-effect transistors (FeFETs), made from ferroelectric hafnium oxide (HfO2), have demonstrated promising SHG capabilities due to their unique symmetric transfer curves...Based on this, we propose and experimentally demonstrate the generation of the difference and of the sum of two input frequencies (frequency mixing) with a single FeFET, which we attribute to the inherently strong quadratic component of the symmetric transfer characteristics. Due to the reversible and continuous ferroelectric switching in HfO2, our approach allows for an electrical control of the energy distribution of spectral components, thus opening up new and very promising paths for frequency manipulations with simple ferroelectric devices.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Review, Journal:  Polarization Switching in 2D Nanoscale Ferroelectrics: Computer Simulation and Experimental Data Analysis. (Pubmed Central) -  Sep 20, 2020   
    A review is given of the experimental results for two-dimensional (2D) films of a ferroelectric polymer, nanosized barium titanate nanofilms, and hafnium oxide-based films...Boltzmann function fitting data enabled us to correctly estimate the region sizes of the homogeneous switching in which the LGD theory is valid. These sizes contain several lattice constants or monolayers of a nanosized ferroelectrics.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Revealing Antiferroelectric Switching and Ferroelectric Wakeup in Hafnia by Advanced Piezoresponse Force Microscopy. (Pubmed Central) -  Sep 2, 2020   
    Hafnium oxide (HfO)-based ferroelectrics offer remarkable promise for memory and logic devices in view of their compatibility with traditional silicon complementary metal oxide semiconductor (CMOS) technology, high switchable polarization, good endurance, and thickness scalability...This result could be explained using polarization switching spectroscopy which revealed antiferroelectric-like switching in the form of pinched hysteresis loops as well as increasing remnant response with repeated cycling. As such, our results offer a promising route for material scientists who want to explore the nanoscale origins of antiferroelectricity and ferroelectric wakeup in HfO.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    [VIRTUAL] Ultrasmall hafnium oxide nanoparticles for the detection of bone microdamage using color spectral CT (On Demand Oral) -  Aug 20, 2020 - Abstract #ACSFall2020ACS-Fall_3870;    
    Due to their small sub 5 nm size, hafnia nanoparticles are excreted through reticuloendothelial system organs without noticeable aggregation while not triggering any adverse side effects based on histological and liver enzyme function assessments. These preclinical studies highlight the potential of HfO2 based nanoparticle contrast agents for skeletal system diseases due to their well placed K edge binding energy.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, PharmaEngine
    Journal:  Pseudo-Interface Switching of a Two-Terminal TaOn n /HfO Synaptic Device for Neuromorphic Applications. (Pubmed Central) -  Aug 14, 2020   
    In order to overcome this dilemma, we proposed pseudo interface-type switching, and obtained excellent retention, decent endurance, and a variety of conductance levels that can be modulated by pulse response. The recognition rate calculated by the neural network simulation using the Fashion Modified National Institute of Standards and Technology database (MNIST) dataset, and the measured conductance values show that pseudo interface-type switching produces results that are similar to those of an interface-type device.